Plasma tau and neurodegenerative markers as predictors of rate of AD progression

项目摘要： 阿尔茨海默病和相关痴呆症（ADRD）影响着世界各地数千万人， 对患者、家庭和医疗保健系统来说都是一个巨大的挑战。对于一些谁目前与 轻度认知障碍，认知和功能迅速恶化，而对于其他人， 进展速度可能不存在或慢得多。了解这种进展速度的变异性是 对患者、家庭和临床研究人员都至关重要，并且通常不能很好地预测， 临床可用的生物标志物工具。基于血液的AD病理学和神经退行性变的标志物 由于它们的非侵入性、成本低， 相对于神经成像，并且缺乏限制其使用的医学禁忌症。在这里，我们检查一组 新开发的基于血液的AD生物标志物（包括神经丝轻链，磷酸化-tau种类，tau， 和Ab片段），其可以填补该缺口。利用从大型诊所前瞻性采集的样本 从人群和当地临床研究中，我们将确定这些血浆指标与 可变的“真实世界”认知和功能下降率，以及基于成像的测量， 神经变性和AD病理进展。

Project Abstract: Alzheimer's disease and related dementias (ADRD) affect tens of millions of people around the world and represent a staggering challenge for patients, families, and healthcare systems. For some who present with mild levels of cognitive impairment, there is rapid worsening of cognition and function, whereas for others, the rate of progression can be absent or much slower. Understanding this variability in rate of progression is critically important to patients, families, and clinical researchers alike, and is not well-predicted by common, clinically available biomarker tools. Blood-based markers of AD pathology and neurodegeneration have potential for widespread use in clinical research and even clinical care, due to their non-invasiveness, cost relative to neuroimaging, and lack of medical contraindications to limit their use. Here we examine a set of newly developed, blood-based AD biomarkers (including neurofilament light chain, phospho-tau species, tau, and Ab fragments) that may fill this gap. Leveraging prospectively acquired samples from a large clinic population and from local clinical research studies, we will determine how these plasma measures relate to variable rates of "real-world" cognitive and functional decline, as well as to imaging-based measures of neurodegeneration and AD pathologic progression.